1-6 of 6
Takashi Nakada
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models

Hirokazu Suzuki, Shotaro Nagase, Chiemi Saito, Atsuko Takatsuka, Motoko Nagata, Kokichi Honda, Yuki Kaneda, Yumi Nishiya, Tomoyo Honda, Tomomichi Ishizaka, Kensuke Nakamura, Takashi Nakada, Yuki Abe, Toshinori Agatsuma
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (3): 257–271.
https://doi.org/10.1158/1535-7163.MCT-23-0287
Published: 04 March 2024
View articletitled, Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models
Open the PDF for Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models in another window
Includes: Supplementary data
Journal Articles

DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models

Michiko Yamato, Jun Hasegawa, Takanori Maejima, Chiharu Hattori, Kazuyoshi Kumagai, Akiko Watanabe, Yumi Nishiya, Tomoko Shibutani, Tetsuo Aida, Ichiro Hayakawa, Takashi Nakada, Yuki Abe, Toshinori Agatsuma
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (4): 635–646.
https://doi.org/10.1158/1535-7163.MCT-21-0554
Published: 01 April 2022
View articletitled, DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models
Open the PDF for DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells

Daisuke Okajima, Satoru Yasuda, Takanori Maejima, Tsuyoshi Karibe, Ken Sakurai, Tetsuo Aida, Tadashi Toki, Junko Yamaguchi, Michiko Kitamura, Reiko Kamei, Tomomichi Fujitani, Tomoyo Honda, Tomoko Shibutani, Sumie Muramatsu, Takashi Nakada, Riki Goto, Shu Takahashi, Miki Yamaguchi, Hirofumi Hamada, Yutaka Noguchi, Masato Murakami, Yuki Abe, Toshinori Agatsuma
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12): 2329–2340.
https://doi.org/10.1158/1535-7163.MCT-21-0206
Published: 01 December 2021
View articletitled, Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
Open the PDF for Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells in another window
Includes: Supplementary data
Journal Articles

Abstract C026: DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models

Daisuke Okajima, Junko Yamaguchi, Michiko Kitamura, Reiko Kamei, Takanori Maejima, Tomoko Shibutani, Satoru Yasuda, Tadashi Toki, Tsuyoshi Karibe, Tomomichi Fujitani, Takashi Nakada, Riki Goto, Yutaka Noguchi, Yuki Abe, Toshinori Agatsuma
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C026.
https://doi.org/10.1158/1535-7163.TARG-19-C026
Published: 01 December 2019
View articletitled, Abstract C026: DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models
Journal Articles

Abstract A027: Combination of TROP2 and SLFN11 as the sensitivity biomarkers for DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd

Satoru Yasuda, Daisuke Okajima, Tadashi Toki, Junko Yamaguchi, Tsuyoshi Karibe, Tomomichi Fujitani, Takashi Nakada, Yutaka Noguchi, Masato Murakami
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A027.
https://doi.org/10.1158/1535-7163.TARG-19-A027
Published: 01 December 2019
View articletitled, Abstract A027: Combination of TROP2 and SLFN11 as the sensitivity biomarkers for DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd
Journal Articles

Abstract A145: DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a potent anti-tumor efficacy with differentiation from T-DM1 in preclinical studies

Yusuke Ogitani, Junko Yamaguchi, Chiaki Ishii, Takehiro Hirai, Ryo Atsumi, Koji Morita, Ichiro Hayakawa, Hiroyuki Naito, Takeshi Masuda, Takashi Nakada, Takahiro Jikoh
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A145.
https://doi.org/10.1158/1535-7163.TARG-15-A145
Published: 01 December 2015
View articletitled, Abstract A145: DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a potent anti-tumor efficacy with differentiation from T-DM1 in preclinical studies